Teleflex Reports Third Quarter Financial Results and Full Year 2024 Outlook Form 8 K

Teleflex Reports Third Quarter Financial Results and Full Year 2024 Outlook

Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the third quarter ended September 29, 2024.

Third quarter financial summary

•GAAP revenue of $764.4 million, up 2.4% compared to the prior year period, up 2.2% on a constant currency basis

•GAAP diluted EPS from continuing operations of $2.36, compared to $2.91 in the prior year period

•Adjusted diluted EPS from continuing operations of $3.49, compared to $3.64 in the prior year period

2024 guidance summary

•Lowering GAAP revenue growth guidance range to 2.90% to 3.40%

•Lowering adjusted constant currency revenue growth guidance range to 3.50% to 4.00%

•Raising GAAP EPS from continuing operations guidance range to $6.65 to $6.95

•Raising the low end of adjusted diluted EPS from continuing operations guidance range to $13.90 to $14.20

"In the third quarter, we delivered year-over-year margin expansion and continued adjusted operating income growth" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "The benefits of our diversified portfolio were evident as strong performances from Interventional and Vascular Access helped offset unexpected softness in OEM revenues. Healthy revenue momentum for Barrigel continued while our integration of Palette Life Sciences AB remained on schedule. Cash flow remains strong, and we have augmented our disciplined capital allocation strategy with a $500 million share repurchase authorization, including a $200 million accelerated share program in the third quarter. With net leverage at 1.7x, we continue to have considerable balance sheet flexibility to execute on our M&A strategy. Finally, we have raised the low end of our 2024 adjusted EPS guidance."

1

NET REVENUE BY SEGMENT

The following table provides information regarding net revenues in each of the Company's reportable operating segments for the three and nine months ended September 29, 2024 and the comparable prior year periods on a GAAP, adjusted and adjusted constant currency basis.

Three Months Ended
As reported	Adjusted
September 29, 2024	October 1, 2023	Reported Revenue Growth	September 29, 2024	October 1, 2023	Adjusted Constant Currency Revenue Growth
Americas	$433.3	$428.2	1.2%	$433.3	$428.2	1.5%
EMEA	150.2	142.7	5.3%	150.2	142.7	3.9%
Asia	98.3	93.2	5.5%	98.3	93.2	5.0%
OEM	82.6	82.3	0.3%	82.6	82.3	0.1%
Consolidated	$764.4	$746.4	2.4%	$764.4	$746.4	2.2%

Nine Months Ended
As reported	Adjusted
September 29, 2024	October 1, 2023	Reported Revenue Growth	September 29, 2024	October 1, 2023	Adjusted Constant Currency Revenue Growth
Americas	$1,266.4	$1,264.7	0.1%	$1,266.4	$1,264.7	0.2%
EMEA	456.9	433.9	5.3%	470.7	433.9	7.8%
Asia	269.5	258.6	4.2%	269.5	258.6	6.5%
OEM	259.1	243.4	6.4%	259.1	243.4	6.3%
Consolidated	$2,251.9	$2,200.6	2.3%	$2,265.7	$2,200.6	3.1%

NET REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding net revenues in each of the Company's global product categories for the three and nine months ended September 29, 2024 and the comparable prior year periods on a GAAP, adjusted and adjusted constant currency basis.

Three Months Ended
As reported	Adjusted
September 29, 2024	October 1, 2023	Reported Revenue Growth	September 29, 2024	October 1, 2023	Adjusted Constant Currency Revenue Growth
Vascular Access	$180.9	$169.9	6.5%	$180.9	$169.9	6.3%
Interventional	149.9	134.1	11.8%	149.9	134.1	11.4%
Anesthesia	101.1	97.6	3.6%	101.1	97.6	3.4%
Surgical	111.7	112.8	(0.9)%	111.7	112.8	(1.0)%
Interventional Urology	83.4	73.6	13.3%	83.4	73.6	13.3%
OEM	82.6	82.3	0.3%	82.6	82.3	0.1%
Other	54.8	76.1	(28.0)%	54.8	76.1	(28.3)%
Consolidated	$764.4	$746.4	2.4%	$764.4	$746.4	2.2%

2

Nine Months Ended
As reported	Adjusted
September 29, 2024	October 1, 2023	Reported Revenue Growth	September 29, 2024	October 1, 2023	Adjusted Constant Currency Revenue Growth
Vascular Access	$543.3	$521.3	4.2%	$543.3	$521.3	4.3%
Interventional	425.7	375.8	13.3%	425.7	375.8	13.4%
Anesthesia	300.0	291.8	2.8%	300.0	291.8	2.9%
Surgical	328.6	317.8	3.4%	328.6	317.8	4.0%
Interventional Urology	246.2	226.8	8.6%	246.2	226.8	8.8%
OEM	259.1	243.4	6.4%	259.1	243.4	6.3%
Other (1)	149.0	223.7	(33.4)%	162.8	223.7	(27.3)%
Consolidated	$2,251.9	$2,200.6	2.3%	$2,265.7	$2,200.6	3.1%

(1) In 2024, amounts reflect the impact from increases in our reserves related to the Italian payback measure pertaining to prior years.

OTHER FINANCIAL HIGHLIGHTS

•Depreciation expense, amortization of intangible assets and deferred financing charges for the nine months ended September 29, 2024 totaled $205.4 million compared to $180.5 million for the prior year period.

•Total cash, cash equivalents and restricted cash equivalents at September 29, 2024 were$277.8 million compared to $222.8 million at December 31, 2023.

•Net accounts receivable at September 29, 2024 were $470.3 million compared to $443.5 million at December 31, 2023.

•Inventories at September 29, 2024 were $639.9 million compared to $626.2 million at December 31, 2023.

2024 OUTLOOK

The Company lowered its full year 2024 revenue growth outlook on a GAAP basis from a range of 3.40% to 4.40% to a range of 2.90% to 3.40%, including our estimate of an approximately 0.15% negative impact of foreign exchange rate fluctuations. On an adjusted constant currency basis, the Company lowered its full year 2024 revenue growth outlook from a range of 4.25% to 5.25% to a range of 3.50% to 4.00% year-over-year.

The Company raised its full year 2024 GAAP diluted earnings per share from continuing operations outlook from a range of $6.43 to $6.83 to a range of $6.65 to $6.95, representing a year-over-year change of (12.0)% to (8.1)%. The Company raised the low end of its full year 2024 adjusted diluted earnings per share from continuing operations guidance from a range of $13.80 to $14.20 to a range of $13.90 to $14.20, representing growth of 2.8% to 5.0% year-over-year.

Forecasted 2024 Adjusted Constant Currency Revenue Growth Reconciliation

Low	High
Forecasted 2024 GAAP revenue growth	2.90%	3.40%
Estimated impact of foreign currency exchange rate fluctuations	(0.15)%	(0.15)%
Italian payback measure	(0.45)%	(0.45)%
Forecasted 2024 adjusted constant currency revenue growth	3.50%	4.00%

Forecasted 2024 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

3

Low	High
Forecasted GAAP diluted earnings per share from continuing operations	$6.65	$6.95
Restructuring, restructuring related and impairment items, net of tax	$0.60	$0.60
Acquisition, integration and divestiture related items, net of tax	$0.30	$0.30
Pension termination and related charges, net of tax	$1.70	$1.70
ERP Implementation, net of tax	$0.32	$0.32
MDR, net of tax	$0.18	$0.18
Italian payback measure, net of tax	$0.29	$0.29
Intangible amortization expense, net of tax	$3.81	$3.81
Tax adjustments	$0.05	$0.05
Forecasted adjusted diluted earnings per share from continuing operations, net of tax	$13.90	$14.20

4

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

A webcast of Teleflex's third quarter 2024 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on October 31, 2024.

An audio replay of the investor call will be available beginning at 11:00 am ET on October 31, 2024, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The confirmation code is 69028.

ADDITIONAL NOTES

References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as "GAAP".In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: adjusted revenue, adjusted constant currency revenue growth and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below.Management uses these financial measures to assess Teleflex's financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management's assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

Tables reconciling changes in historical adjusted constant currency net revenues and adjusted net revenues to historical GAAP net revenues and historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below.

Adjusted revenue:This non-GAAP measure is based upon net revenues, adjusted to exclude the impact in the nine months ended September 29, 2024 of an increase in our reserves, and corresponding reduction to revenue within our EMEA segment, for prior years. The reserve relates to the Italian payback measure, a law that requires suppliers of

5

medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a recent ruling from the Italian courts, we recognized an increase in our reserves during the nine months ended September 29, 2024, of which $13.8 million related to prior years. The prior year amounts do not represent normal adjustments to revenue, are not expected to recur in future periods and are not recurring in nature, making it difficult to contribute to a meaningful evaluation of our operating performance. Accordingly, management has excluded the $13.8 million prior year amount as it is not indicative of our underlying core performance or business trends.

Adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Restructuring, restructuring related and impairment items -Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements

6

and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Italian payback measure - These adjustments represent the exclusion of the impact from increases in our reserves related to the Italian payback measure pertaining to prior years as described in Adjusted revenue.

Pension termination and related charges - These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental expenses including certain charges stemming from the liquidation of surplus plan assets. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur once the plan termination process has been completed.Accordingly, management has excluded these amounts to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

European medical device regulation - The European Union ("EU") has adopted the EU Medical Device Regulation ("MDR"), which replaces the existing Medical Devices Directive ("MDD") and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense -Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

ERP implementation -These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

Tax adjustments -These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

7

Reconciliation of Net Revenue (Dollars in millions)

Net revenue by segment

Three Months Ended	% Increase / (Decrease)
September 29, 2024	October 1, 2023
Reported revenue	Adjustment	Adjusted Revenue	Reported revenue	Adjustment	Adjusted Revenue	Reported Revenue Growth	Currency Impact	Adjustment impact	Adjusted Constant Currency Revenue Growth
Americas	$433.3	$-	$433.3	$428.2	$-	$428.2	1.2%	(0.3)%	-%	1.5%
EMEA	150.2	-	150.2	142.7	-	142.7	5.3%	1.4%	-%	3.9%
Asia	98.3	-	98.3	93.2	-	93.2	5.5%	0.5%	-%	5.0%
OEM	82.6	-	82.6	82.3	-	82.3	0.3%	0.2%	-%	0.1%
Consolidated	$764.4	$-	$764.4	$746.4	$-	$746.4	2.4%	0.2%	-%	2.2%

Nine Months Ended	% Increase / (Decrease)
September 29, 2024	October 1, 2023
Reported revenue	Adjustment	Adjusted Revenue	Reported revenue	Adjustment	Adjusted Revenue	Reported Revenue Growth	Currency Impact	Adjustment impact	Adjusted Constant Currency Revenue Growth
Americas	$1,266.4	$-	$1,266.4	$1,264.7	$-	$1,264.7	0.1%	(0.1)%	-%	0.2%
EMEA	456.9	(13.8)	470.7	433.9	-	433.9	5.3%	0.7%	(3.2)%	7.8%
Asia	269.5	-	269.5	258.6	-	258.6	4.2%	(2.3)%	-%	6.5%
OEM	259.1	-	259.1	243.4	-	243.4	6.4%	0.1%	-%	6.3%
Consolidated	$2,251.9	($13.8)	$2,265.7	$2,200.6	$-	$2,200.6	2.3%	(0.2)%	(0.6)%	3.1%

Net revenue by global product category

Three Months Ended	% Increase / (Decrease)
September 29, 2024	October 1, 2023
Reported revenue	Adjustment	Adjusted Revenue	Reported revenue	Adjustment	Adjusted Revenue	Reported Revenue Growth	Currency Impact	Adjustment impact	Adjusted Constant Currency Revenue Growth
Vascular Access	$180.9	$-	$180.9	$169.9	$-	$169.9	6.5%	0.2%	-%	6.3%
Interventional	149.9	-	149.9	134.1	-	134.1	11.8%	0.4%	-%	11.4%
Anesthesia	101.1	-	101.1	97.6	-	97.6	3.6%	0.2%	-%	3.4%
Surgical	111.7	-	111.7	112.8	-	112.8	(0.9)%	0.1%	-%	(1.0)%
Interventional Urology	83.4	-	83.4	73.6	-	73.6	13.3%	-%	-%	13.3%
OEM	82.6	-	82.6	82.3	-	82.3	0.3%	0.2%	-%	0.1%
Other (1)	54.8	-	54.8	76.1	-	76.1	(28.0)%	0.3%	-%	(28.3)%
Consolidated	$764.4	$-	$764.4	$746.4	$-	$746.4	2.4%	0.2%	-%	2.2%

8

Nine Months Ended	% Increase / (Decrease)
September 29, 2024	October 1, 2023
Reported revenue	Adjustment	Adjusted Revenue	Reported revenue	Adjustment	Adjusted Revenue	Reported Revenue Growth	Currency Impact	Adjustment impact	Adjusted Constant Currency Revenue Growth
Vascular Access	$543.3	$-	$543.3	$521.3	$-	$521.3	4.2%	(0.1)%	-%	4.3%
Interventional	425.7	-	425.7	375.8	-	375.8	13.3%	(0.1)%	-%	13.4%
Anesthesia	300.0	-	300.0	291.8	-	291.8	2.8%	(0.1)%	-%	2.9%
Surgical	328.6	-	328.6	317.8	-	317.8	3.4%	(0.6)%	-%	4.0%
Interventional Urology	246.2	-	246.2	226.8	-	226.8	8.6%	(0.2)%	-%	8.8%
OEM	259.1	-	259.1	243.4	-	243.4	6.4%	0.1%	-%	6.3%
Other (1)	149.0	(13.8)	162.8	223.7	-	223.7	(33.4)%	-%	(6.1)%	(27.3)%
Consolidated	$2,251.9	($13.8)	$2,265.7	$2,200.6	$-	$2,200.6	2.3%	(0.2)%	(0.6)%	3.1%

(1) In 2024, amounts reflect the impact from increases in our reserves related to the Italian payback measure pertaining to prior years.

Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

Three Months Ended September 29, 2024
Revenue	Gross margin	SG&A (1)	R&D (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
GAAP Basis	$764.4	56.3%	31.6%	5.1%	19.5%	$130.6	$19.6	15.0%	$2.36
Adjustments
Restructuring, restructuring related and impairment items (A)	-	0.7	(0.1)	-	0.9	6.8	1.2	0.12
Acquisition, integration and divestiture related items (B)	-	-	(0.3)	-	0.3	2.0	-	0.04
ERP implementation	-	-	(0.8)	-	0.8	6.1	1.0	0.11
MDR	-	-	-	(0.2)	0.2	1.3	-	0.03
Pension termination costs	-	0.7	-	(0.7)	(5.4)	(1.3)	(0.09)
Intangible amortization expense	-	3.8	(2.5)	-	6.3	48.3	5.2	0.92
Adjustments total	-	4.5	(3.0)	(0.2)	7.8	59.1	6.1	1.13
Adjusted basis	$764.4	60.8%	28.6%	4.9%	27.3%	$189.7	$25.7	13.6%	$3.49

9

Three Months Ended October 1, 2023
Gross margin	SG&A (1)	R&D (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
GAAP Basis	55.8%	28.6%	5.0%	22.1%	$149.6	$11.9	8.0%	$2.91
Adjustments
Restructuring, restructuring related and impairment items (A)	0.5	-	-	0.6	4.7	0.7	0.08
Acquisition, integration and divestiture related items (B)	-	2.0	-	(2.0)	(14.8)	0.2	(0.32)
ERP implementation	-	-	-	-	0.3	0.1	-
MDR	-	-	(0.8)	0.8	5.7	-	0.12
Intangible amortization expense	3.1	(2.6)	-	5.7	41.6	2.1	0.85
Tax adjustments	-	-	-	-	-	-	-
Adjustments total	3.6	(0.6)	(0.8)	5.1	37.5	3.1	0.73
Adjusted basis	59.4%	28.0%	4.2%	27.2%	$187.1	$15.0	8.0%	$3.64

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.

(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues.

Totals may not sum due to rounding.

Nine Months Ended September 29, 2024
Revenue	Gross margin	SG&A (1)	R&D (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
GAAP Basis	$2,251.9	56.1%	38.8%	5.2%	11.6%	$202.2	$(4.6)	(2.3)%	$4.38
Adjustments
Restructuring, restructuring related and impairment items (A)	-	0.5	(0.1)	-	1.1	24.8	4.3	0.44
Acquisition, integration and divestiture related items (B)	-	0.1	(0.4)	-	0.5	11.0	0.5	0.22
Italian payback measure (C)	13.8	0.2	(0.2)	-	0.6	13.8	-	0.29
ERP implementation	-	-	(0.4)	-	0.4	9.2	1.4	0.17
MDR	-	-	-	(0.4)	0.3	7.6	-	0.16
Pension termination costs	-	-	(5.9)	-	5.9	133.2	56.9	1.61
Intangible amortization expense	-	4.0	(2.6)	-	6.5	148.0	15.2	2.81
Tax adjustments	-	-	-	-	-	-	(2.1)	0.04
Adjustments total	13.8	4.8	(9.6)	(0.4)	15.3	347.6	76.2	5.74
Adjusted basis	$2,265.7	60.9%	29.2%	4.8%	26.9%	$549.8	$71.6	13.0%	$10.12

10

Nine Months Ended October 1, 2023
Gross margin	SG&A (1)	R&D (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
GAAP Basis	55.2%	30.4%	5.4%	19.3%	$374.0	$47.7	12.7%	$6.90
Adjustments
Restructuring, restructuring related and impairment items (A)	0.9	-	(0.1)	1.3	27.5	4.2	0.49
Acquisition, integration and divestiture related items (B)	-	0.9	-	(0.9)	(19.3)	0.3	(0.41)
ERP implementation	-	(0.1)	-	0.1	2.8	0.7	0.05
MDR	-	-	(1.1)	1.1	23.6	-	0.50
Intangible amortization expense	3.2	(2.6)	-	5.6	125.3	6.2	2.51
Tax adjustments	-	-	-	-	-	(4.8)	0.10
Adjustments total	4.1	(1.8)	(1.2)	7.2	159.9	6.6	3.24
Adjusted basis	59.3%	28.6%	4.2%	26.5%	$533.9	$54.3	10.2%	$10.14

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.

(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues.

Totals may not sum due to rounding.

Tickmarks to Reconciliation Tables

(A)Restructuring, restructuring related and impairment items - For the three months ended September 29, 2024, pre-tax restructuring charges were $0.3 million and restructuring related charges were $6.5 million. For the three months ended October 1, 2023, pre-tax restructuring charges were $0.2 million and restructuring related charges were $4.5 million.For the nine months ended September 29, 2024, pre-tax restructuring charges were $8.7 million; restructuring related charges were $14.0 million; and impairment charges were $2.1 million. For the nine months ended October 1, 2023, pre-tax restructuring charges were $4.0 million and restructuring related charges were $23.6 million.

(B)Acquisition, integration and divestiture related items - For the three and nine months ended September 29, 2024 and October 1, 2023, these charges related to changes in the estimated fair value of our contingent consideration liabilities and the acquisition of Palette Life Sciences AB.

(C)Italian payback measure - Adjustment reflects the impact of an increase in reserves for prior years related to the Italian payback measure and its impact on the adjusted basis for each Non-GAAP financial measure presented within the table.

11

ABOUT TELEFLEX INCORPORATED

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ - trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, our ability to execute on our M&A strategy; forecasted 2024 GAAP and adjusted constant currency revenue growth and GAAP and adjusted diluted earnings per share; and our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2024 financial results. Actual results could differ materially from those in the forward-looking statements due to, among other things, delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; the inability of acquired businesses to generate revenues in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

12

TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

Three Months Ended	Nine Months Ended
September 29, 2024	October 1, 2023	September 29, 2024	October 1, 2023
(Dollars and shares in thousands, except per share)
Net revenues	$	764,375	$	746,389	$	2,251,915	$	2,200,580
Cost of goods sold	334,203	330,078	989,151	985,066
Gross profit	430,172	0	416,311	1,262,764	1,215,514
Selling, general and administrative expenses	247,257	213,194	740,718	669,216
Research and development expenses	38,726	37,576	117,119	118,493
Pension settlement charge	(5,407)	-	132,732	-
Restructuring and impairment charges	285	231	10,799	3,960
Income from continuing operations before interest and taxes	149,311	165,310	261,396	423,845
Interest expense	21,058	23,192	64,909	59,291
Interest income	(2,298)	(7,487)	(5,751)	(9,486)
Income from continuing operations before taxes	130,551	149,605	202,238	374,040
Taxes (benefit) on income from continuing operations	19,633	11,935	(4,586)	47,651
Income from continuing operations	110,918	137,670	206,824	326,389
Operating income (loss) from discontinued operations	112	(687)	(639)	(1,512)
Taxes (benefit) on operating loss from discontinued operations	26	(157)	(146)	(346)
Income (loss) from discontinued operations	86	(530)	(493)	(1,166)
Net income	$	111,004	$	137,140	$	206,331	$	325,223
Earnings per share:
Basic:
Income from continuing operations	$	2.37	$	2.93	$	4.40	$	6.95
Income (loss) from discontinued operations	0.01	(0.01)	(0.01)	(0.03)
Net income	$	2.38	$	2.92	$	4.39	$	6.92
Diluted:
Income from continuing operations	$	2.36	$	2.91	$	4.38	$	6.90
Loss from discontinued operations	-	(0.01)	(0.01)	(0.02)
Net income	$	2.36	$	2.90	$	4.37	$	6.88
Weighted average common shares outstanding
Basic	46,724	46,992	46,995	46,974
Diluted	47,012	47,299	47,256	47,304

13

TELEFLEX INCORPORATED

CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 29, 2024	December 31, 2023
(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	243,235	$	222,848
Accounts receivable, net	470,257	443,467
Inventories	639,938	626,216
Prepaid expenses and other current assets	116,928	107,471
Prepaid taxes	28,945	7,404
Total current assets	1,499,303	1,407,406
Property, plant and equipment, net	512,224	479,913
Operating lease assets	112,895	123,521
Goodwill	2,918,562	2,914,055
Intangible assets, net	2,325,105	2,501,960
Deferred tax assets	6,779	6,748
Other assets	111,423	98,943
Total assets	$	7,486,291	$	7,532,546
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	96,875	$	87,500
Accounts payable	119,255	132,247
Accrued expenses	157,782	146,880
Payroll and benefit-related liabilities	142,619	146,535
Accrued interest	16,657	5,583
Income taxes payable	18,681	41,453
Other current liabilities	66,884	46,547
Total current liabilities	618,753	606,745
Long-term borrowings	1,661,546	1,727,572
Deferred tax liabilities	445,841	456,080
Pension and postretirement benefit liabilities	23,548	23,989
Noncurrent liability for uncertain tax positions	3,369	3,370
Noncurrent operating lease liabilities	102,938	111,300
Other liabilities	148,579	162,502
Total liabilities	3,004,574	3,091,558
Commitments and contingencies
Total shareholders' equity	4,481,717	4,440,988
Total liabilities and shareholders' equity	$	7,486,291	$	7,532,546

14

TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Nine Months Ended
September 29, 2024	October 1, 2023
(Dollars in thousands)
Cash flows from operating activities of continuing operations:
Net income	$	206,331	$	325,223
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	493	1,166
Depreciation expense	54,826	52,687
Intangible asset amortization expense	147,983	125,230
Deferred financing costs and debt discount amortization expense	2,562	2,547
Pension settlement charge	132,732	-
Fair value step up of acquired inventory sold	1,722	-
Changes in contingent consideration	7,446	(24,482)
Assets impairment charge	2,110	-
Stock-based compensation	23,727	22,135
Deferred income taxes, net	(60,648)	2,076
Payments for contingent consideration	-	(289)
Interest benefit on swaps designated as net investment hedges	(12,031)	(15,459)
Other	1,970	4,743
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(25,294)	(18,313)
Inventories	(11,635)	(50,702)
Prepaid expenses and other assets	40,446	7,487
Accounts payable, accrued expenses and other liabilities	(1,623)	(16,674)
Income taxes receivable and payable, net	(75,493)	(45,014)
Net cash provided by operating activities from continuing operations	435,624	372,361
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(94,412)	(63,768)
Payments for businesses and intangibles acquired, net of cash acquired	(120)	(205)
Net proceeds on swaps designated as net investment hedges	18,262	10,275
Proceeds from sales of investments	7,300	7,300
Purchase of investments	(7,300)	(11,300)
Net cash used in investing activities from continuing operations	(76,270)	(57,698)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	130,000	646,000
Reduction in borrowings	(188,375)	(321,625)
Repurchase of common stock	(200,000)	-
Net proceeds from share based compensation plans and related tax impacts	3,555	534
Payments for contingent consideration	(182)	(949)
Dividends paid	(47,808)	(47,919)
Net cash (used in) provided by financing activities from continuing operations	(302,810)	276,041
Cash flows from discontinued operations:
Net cash used in operating activities	(2,355)	(579)
Net cash used in discontinued operations	(2,355)	(579)
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	728	(660)
Net increase in cash, cash equivalents and restricted cash equivalents	54,917	589,465
Cash, cash equivalents and restricted cash equivalents at the beginning of the period	222,848	292,034
Cash, cash equivalents and restricted cash equivalents at the end of the period	$	277,765	$	881,499

15

Contacts:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

investors.teleflex.com

610-948-2836

16